DENVER--(BUSINESS WIRE)--June 21, 2006--Ceragenix Pharmaceuticals, Inc., a biopharmaceutical company focused on infectious disease and dermatology, today announced that it has entered into a research and development agreement with an internationally recognized research laboratory to develop formulations, in the form of nasal ointments, designed to prevent influenza infection and to decolonize the nasal passage of methicillin-resistant staph aureus (MRSA). The nasal ointments will contain the Company’s CSA-13, a member of the class of proprietary Ceragenin(TM) compounds, which has been shown in in vitro testing to prevent influenza infection of epithelial cells and to be highly bactericidal against MRSA. Pending successful formulation, the Company plans on proceeding with further drug development activities.
